Indian Journal of Modern Research and Reviews

This Journal is a member of the *'Committee on Publication Ethics'*

Online ISSN:2584-184X

Research Article

Apathy in Alzheimer's Disease: Neurobiological Mechanisms, Clinical Significance, And Emerging Therapeutic Approaches

Dr. Shahan Layek [1*], Dr. Farheen Azim [2]

[1] Independent Researcher, West Bengal, India

[2] Department of Clinical Medicine, Dali University, China

Corresponding Author: * Dr. Shahan Layek

DOI: https://doi.org/10.5281/zenodo.22111007

Abstract

Apathy is one of the most common yet frequently underrecognized neuropsychiatric manifestations of Alzheimer's disease (AD), affecting approximately 40–70% of patients during the course of the disease. It is characterised by a persistent reduction in goal-directed behaviour, cognitive activity, emotional responsiveness, and motivation, and is clinically distinct from depression, although both conditions may coexist. Apathy is a multidimensional syndrome involving behavioural, cognitive, and affective domains and is commonly assessed using instruments such as the Apathy Evaluation Scale, Apathy Inventory, and Neuropsychiatric Inventory. Its neurobiological basis involves dysfunction of frontal-subcortical and salience-network circuits, particularly the anterior cingulate cortex, prefrontal cortex, basal ganglia, and related motivational pathways. Neuroimaging studies have associated apathy with cortical atrophy, disrupted white-matter connectivity, altered glucose metabolism, and abnormalities in functional connectivity. Dysregulation of dopaminergic, cholinergic, and noradrenergic neurotransmitter systems may further contribute to impaired motivation and reward processing. Emerging evidence also links apathy with amyloid and tau pathology, suggesting that it may serve as an early marker of disease progression. Clinically, apathy is associated with faster cognitive decline, reduced functional independence, poorer quality of life, and increased caregiver burden. Pharmacological approaches, including cholinesterase inhibitors, memantine, and particularly methylphenidate, have demonstrated variable benefits, while non-pharmacological strategies such as structured activities, exercise, multisensory stimulation, caregiver interventions, and technology-assisted engagement show promising results. Future research should emphasise standardised diagnostic criteria, biomarker-based patient stratification, individualised treatment, and digital measures of motivation and activity. A comprehensive, mechanism-based approach integrating pharmacological and behavioural interventions is essential for improving outcomes for individuals with AD-related apathy.

Manuscript Information

- **ISSN No:** 2584-184X
- **Received:** 07-07-2026
- **Accepted:** 22-08-2026
- **Published:** 26-08-2026
- **MRR:**4(8); 2026: 261-265

- **Plagiarism Checked:** Yes
- **Peer Review Process:** Yes

How to Cite this Article

Layek S, Azim F. Apathy In Alzheimer's Disease: Neurobiological Mechanisms, Clinical Significance, And Emerging Therapeutic Approaches. Indian J Mod Res Rev. 2026;4(8):261-265.

Access this Article Online

www.mrrjournal.in

KEYWORDS: Alzheimer's disease; apathy; neuropsychiatric symptoms; motivation; frontal-subcortical circuits; anterior cingulate cortex; dopamine; amyloid; tau; cognitive decline; caregiver burden; pharmacological treatment; non-pharmacological intervention.

INTRODUCTION

Apathy is the most frequent-and the most unrecognised-neuropsychiatric symptom of Alzheimer's disease, occurring in nearly 40-70% of patients throughout the disease progression. Apathy represents a detectable reduction of goal-directedness, as well as cognitive and emotional output, unrelated to depressed mood, reduced arousal level, and physical symptoms of underlying disorders; It clearly distinguishes from the disorder that is most frequently associated with apathy, ie, depression. Notwithstanding its high occurrence and great burden, apathy has to date been one of the least investigated and least treated Alzheimer's disease symptoms.[5]

Defining and Measuring Apathy

Apathy is seen as a multidimensional syndrome in at least 3 dimensions: behavioural (blunted initiation of self-generated actions), cognitive (lacking interest in acquiring novel information or ideas), and emotional/affective (blunted emotional responsibility). Criteria suggested by Robert and associates include lack of drive for more than 4 weeks, impaired functioning in at least two of these 3 dimensions, which results in an impairment of daily living activities, in the absence of other medical/psychiatric illnesses. The two conditions are, to some extent, separate, in that the hallmark of depression is dysphoria/guilt/negative self-appraisal and that of apathy is loss of will/drive. Nonetheless, the two disorders can also occur together, complicating in vivo differential diagnosis.[4]

Assessment tools commonly used include the Apathy Evaluation Scale (AES), the Apathy Inventory, and the apathy subscale of the Neuropsychiatric Inventory (NPI). These instruments rely heavily on informant reports, since patients with apathy often have limited insight into their own reduced motivation—a phenomenon termed anosognosia for apathy, which itself may reflect a distinct neural mechanism involving impaired self-monitoring circuitry.[8]

Neurobiological Mechanisms

Frontal-Subcortical Circuit Disruption

The dominant conceptual framework for apathy across neurodegenerative and neuropsychiatric conditions implicates disruption of frontal-subcortical circuits linking the prefrontal cortex, anterior cingulate cortex (ACC), and basal ganglia. Three parallel circuits are typically described: a dorsolateral prefrontal circuit governing executive function, an orbitofrontal circuit governing social and emotional regulation, and an anterior cingulate circuit governing motivation and drive. Lesions or dysfunction within the anterior cingulate–ventral striatal loop appears most specifically associated with apathy, as this circuit is central to the translation of motivational salience into initiated action. In AD, neurodegeneration does not produce discrete lesions, but rather progressive, network-level dysfunction, and apathy has been most consistently linked to hypometabolism and atrophy within the anterior and medial cingulate cortex, orbitofrontal cortex, and dorsolateral prefrontal regions.[9]

Structural and Functional Imaging Findings

Neuroimaging studies employing structural MRI have repeatedly demonstrated associations between apathy severity and grey matter atrophy in the anterior cingulate cortex, medial and orbital frontal cortex, and insula. Diffusion tensor imaging studies extend this picture by showing that apathy correlates with disruption of white matter tracts connecting these regions, including the anterior cingulum bundle and the uncinate fasciculus, suggesting that apathy in AD reflects not merely regional atrophy but a disconnection syndrome affecting the structural integrity of motivational networks. Functional imaging using PET and resting-state fMRI has shown reduced glucose metabolism and altered connectivity within the salience network, and particularly within nodes shared with the default mode network, in patients with high apathy scores. Some studies further implicate reduced connectivity between the ACC and the nucleus accumbens, mirroring circuitry long implicated in reward processing and motivated behaviour in other contexts.[11]

Neurotransmitter Systems

Various neurotransmitter systems have been hypothesised to underlie apathy. Particularly notable are these relating to the dopaminergic system: it plays a crucial role in anticipation of reward, incentive salience and decision making in reward motivated tasks (investment) and there exists good rationale to assume that reduced dopaminergic tone in mesocorticolimbic pathways, that is within projection to the ventral striatum and to regions of the prefrontal cortex of the ventral tegmental area, could undermine ability translate value of prospective action into an intention to expend energy on this action. This account is also compatible with behavioural economics accounts of apathy conceptualised as an illness of investment-related decision making and is also compatible with theories positing discounting of the perceived value of a future reward as a function of required effort.[14]

The cholinergic system also merits attention, given its centrality to AD pathology more broadly. Degeneration of cholinergic projections from the basal forebrain, particularly the nucleus basalis of Meynert, to cortical and limbic targets has been proposed as a contributor to apathetic symptoms, partly on the basis that cholinesterase inhibitors—the mainstay pharmacological treatment for AD-related cognitive symptoms—have shown modest benefit for apathy in some trials. Noradrenergic depletion secondary to locus coeruleus degeneration, which occurs early and extensively in AD, has similarly been proposed as contributing to reduced arousal and motivational drive, though evidence here remains more preliminary.[16]

Relationship to Amyloid and Tau Pathology

Emerging evidence links apathy directly to the core proteinopathies of AD. Several studies using amyloid PET imaging have found associations between amyloid burden—particularly within frontal regions—and apathy severity, even in prodromal and preclinical stages of disease, suggesting

apathy may not be purely a downstream consequence of advanced neurodegeneration but potentially an early marker of pathological accumulation. Tau imaging studies similarly suggest that tau deposition within limbic and paralimbic structures, including the cingulate and orbitofrontal cortex, tracks with apathy severity, and some work indicates that the relationship between tau burden and apathy may be mediated by structural atrophy in these regions, positioning apathy within the broader neurodegenerative cascade rather than as an epiphenomenon of general cognitive decline.[17]

Clinical and Prognostic Significance

Apathy in AD is not a benign quality-of-life issue-it has significant prognostic implications. Longitudinal studies consistently have shown that apathy is a predictor of more rapid cognitive deterioration, speedier MCI to dementia conversion, and more loss of functional independence, independently of baseline cognitive severity and depression. Apathy is also associated with accelerating brain atrophy on serial imaging, suggesting apathy may be a marker and perhaps driving factor of disease progression, not just a passive comorbid condition.[19]

As for caregivers, the impact is disproportionately burdensome, as patients with apathy increasingly abandon formerly enjoyed activities, engage less in conversation and other social interactions, and frequently struggle with basic activities of daily living. Caregiver burden often increases, along with caregivers' risk of developing depressive disorders, and caregivers will frequently pinpoint apathy-more than the memory loss-as a reason they are considering placing a loved one in a facility. Since apathy tends to be expressed less often by explicit complaint or visible distress, it often gets missed, shrugged off as inevitable with ageing or dementia, or treated at a lesser degree relative to other more apparent behavioural symptoms such as agitation.[21]

Differentiating apathy from depression is of substantial clinical importance because the two conditions may respond differently to treatment and carry different implications: depression in AD may respond to standard antidepressant approaches, whereas apathy has historically shown limited responsiveness to these same agents, and in some cases selective serotonin reuptake inhibitors have been reported to worsen apathetic symptoms, possibly through blunting of dopaminergic reward signaling.[22]

Pharmacological Approaches

No pharmacological agent currently holds regulatory approval specifically for apathy in AD, and the evidence base remains limited by small sample sizes, heterogeneous outcome measures, and inconsistent diagnostic criteria across studies. Nonetheless, several agents have been investigated.

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) have shown modest, inconsistent benefits for apathy in some trials and observational studies, plausibly through augmentation of cholinergic tone within frontal-subcortical circuits, though effect sizes are generally small and apathy is rarely a primary trial endpoint.

Memantine, an NMDA receptor antagonist, has similarly shown mixed results, with some post-hoc analyses of trials designed for cognitive outcomes suggesting benefit for apathy and behavioural symptoms more broadly, though dedicated trials are lacking.

Psychostimulants – with methylphenidate being the most extensively studied form – remain the most evidence-based pharmacology for the targeted treatment of apathy in AD. In ADMET (Apathy in Dementia Methylphenidate Trial) and the successor study ADMET 2, it was found that methylphenidate was associated with small but statistically significant improvements in apathy ratings compared with placebo, together with improvements in some measures of global cognition, with the safety profile being generally tolerable for the subjects, but minor changes in cardiovascular parameters indicate caution is warranted, especially among the subjects with concomitant cardiac conditions. These findings support the hypothesis that apathy in AD involves the dopamine pathway and suggest the use of the psychostimulant in AD-related apathy.[5]

Dopamine agonists and other dopaminergic drugs were the subject of pilot trials with inconclusive outcomes; it was noticed that they could increase the occurrence of the phenomenon of loss of impulse control, along with other neuropsychiatric effects – of major interest for this specific population with predisposition to developing mental disorders.[15]

Ongoing research for novel or reused drugs for apathy: the targets include drugs of the orexin system due to its role as the key factor for awakening and motivational behaviours and drugs interfering with glutamatergic signalling, such as modulators of NMDA receptors. Also, attention is focusing on the possible benefits of drugs used for the treatment of depression, with dopaminergic/noradrenergic action such as bupropion; the lack of controlled studies of their effectiveness specifically for apathy, and the limited scope of effectiveness in the targeted condition still to come soon. [24]

Non-pharmacological Methods

Considering the meagre and unreliable effectiveness of drugs available and under-researched, in this last period more attention was put on non-pharmacological therapies, which can either be utilised as primary treatment options or complementing the medications used. Programs of organised activities and engagement the so-called structured and organised activities and engagement programs"- customised and tailored plans of activities, taking advantage of preserved cognitive capabilities and former habits of the patients, proved useful for alleviating and reducing apathy; the mechanism behind its effectiveness might be lowering the required initiation threshold for actions or substituting the lost initiative with external cueing.[27]

Multisensory interventions: Sensory multi-stimulation (through music, specific environments, Snoezelen-type environments) for those symptoms was reported; although the effect on apathy was small, it could be useful for modulating arousal, reward

and pleasure mechanisms that might not be so deteriorated in the frontal brain.

Exercise interventions, including structured aerobic and resistance training programs, have shown promising effects on apathy in several trials, plausibly mediated through both direct neurobiological effects—such as increased cerebral perfusion and neurotrophic signalling—and through structured, externally scaffolded engagement that reduces reliance on self-generated initiation.[30]

Caregiver-directed interventions that train caregivers in behavioural activation techniques, environmental modification, and communication strategies have shown benefit both for patient apathy and for caregiver burden, reflecting the reality that apathy management often depends as much on environmental and interpersonal scaffolding as on any intervention directed at the patient alone.

Technology-based approaches, including computerised cognitive stimulation, virtual reality-based engagement programs, and social robotics, represent an emerging area of interest, with preliminary studies suggesting feasibility and modest symptomatic benefit, though larger controlled trials are needed to establish efficacy and identify which patient subgroups are most likely to benefit.

Future Directions

Future Directions: We conclude by outlining future priorities that should guide the research agenda.

The first, most critical priority is the development of standard, agreed-upon diagnostic criteria and outcome metrics for apathy, facilitating appropriate meta-analysis and cross-study comparisons both ofpharmacologicalandnon-pharmacologicalinvestigators, since the broad range of published measures of apathy has severely attenuated the interpretability of current study results. [5]

Second, patient stratification based on biomarker profiles, including amyloid PET, tau PET, and functional connectivity measures, should serve to demarcate subtypes of apathy with varying underpinning mechanisms, who may be responsive to different therapeutic interventions; such stratification will promote a more individualised, patient-centred therapeutic approach.

Third, because dopaminergic signalling, as well as effort related to decision-making, appears to be of major importance, additional investigation of less stimulating and safer dopaminergic medications remains necessary.[17]

Fourth, the use of mobile sensing and computational approaches to establish the degree of loss of initiative, which can be evaluated passively by tracking movement and interactions with devices (digital phenotyping), is likely to serve as more sensitive and ecological measures than informant-based tools, speeding up all areas of research, from mechanistic to treatment research.[30]

CONCLUSION

This post previously ran on Alzheimer's Disease. Alzheimer-Associated Apathy is a pervasive, biologically and symptomatically meaningful disease, driven by the disruption of frontal-subcortical and salience network circuitry, with ever-growing associations to primary AD proteinopathy [9]. As much or more in magnitude than more openly impairing neuropsychiatric features to AD prognosis, impact upon AD outcomes, and strain upon caregivers, apathy tends to be less examined or discussed in treatment and research. Enhancing knowledge in this field and improving treatment and care depend on detailed clinical phenotyping of apathy in AD, mechanistically guided trial design, and a therapeutic palette encompassing pharmacologic and behavioural approaches designed around apathy's underlying neural substrates and related maladjustments in motivational systems.[24.]

Declaration:

Conflict of Interest: All authors have declared that there is no conflict of interest.

Funding: No source of funding was used for this study.

Acknowledgements: The authors gratefully thank every investigator and researcher to use their contributed articles for this research. Consent for Publication: All authors have read and approved the final manuscript.

REFERENCE

1. Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer's disease. J Am Geriatr Soc. 2001;49(12):1700-1707.
2. Onyike CU, Sheppard JM, Tschanz JT, Norton MC, Green RC, Steinberg M, et al. Epidemiology of apathy in older adults: The Cache County Study. Am J Geriatr Psychiatry. 2007;15(5):365-375.
3. Marin RS. Apathy: A neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243-254.
4. Robert P, Onyike CU, Leentjens AFG, Dujardin K, Aalten P, Starkstein S, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry. 2009;24(2):98-104.
5. Lanctôt KL, Agüera-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, et al. Apathy associated with neurocognitive disorders: Recent progress and future directions. Alzheimers Dement. 2017;13(1):84-100.
6. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38(2):143-162.
7. Robert PH, Clairet S, Benoit M, Koutaich J, Bertogliati C, Tible O, et al. The Apathy Inventory: Assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002;17(12):1099-1105.
8. Cummings JL, Mega M, Grey K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314.

9. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006;16(7):916-928.
10. Benoit M, Berrut G, Doussaint J, Bakchine S, Bonin-Guillaume S, Frémont P, et al. Apathy and depression in mild Alzheimer's disease are associated with distinct patterns of brain activation. J Neurol Neurosurg Psychiatry. 2002;73(3):261-265.
11. Guercio BJ, Donovan NJ, Munro CE, Aghjayan SL, Wigman SE, Locascio JJ, et al. Structural MRI correlates of apathy in Alzheimer's disease and mild cognitive impairment. Neuropsychologia. 2015;68:1-7.
12. Tunnard C, Whitehead D, Hurt C, Wahlund LO, Mecocci P, Tsolaki M, et al. Apathy and cortical atrophy in Alzheimer's disease. Int J Geriatr Psychiatry. 2011;26(7):741-748.
13. Balthazar MLF, Pereira FRS, Lopes TM, da Silva EL, Coan AC, Campos BM, et al. Neuropsychiatric symptoms in Alzheimer's disease are related to functional connectivity alterations in the default mode network. J Alzheimers Dis. 2014;42(4):1207-1216.
14. Husain M, Roiser JP. Neuroscience of apathy and anhedonia: A transdiagnostic approach. Nat Rev Neurosci. 2018;19(8):470-484.
15. Birks JS. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1): CD005593.
16. Chalermpalanupap T, Weinshenker D, Rorabaugh JM. Down but not out: The role of the locus coeruleus in Alzheimer's disease. J Alzheimers Dis. 2017;57(3):631-647.
17. Marshall GA, Monserratt L, Harwood D, Mandelkern MA, Cummings JL, Sultzer DL. Greater regional cortical amyloid burden is associated with apathy in mild cognitive impairment and Alzheimer's disease. Arch Neurol. 2013;70(4):514-520.
18. Gatchel JR, Donovan NJ, Locascio JJ, Becker JA, Rentz DM, Johnson KA, et al. Regional tau pathology and apathy in Alzheimer's disease. Brain. 2017;140(12):3216-3226.
19. Clarke DE, Ko JY, Lyketsos C, Rebok GW, Eaton WW. Apathy and cognitive decline in Alzheimer's disease. Am J Geriatr Psychiatry. 2010;18(8):713-720.
20. van der Linde RM, Matthews FE, Dening T, Brayne C. Patterns and persistence of behavioural and psychological symptoms in dementia. Int Psychogeriatr. 2016;28(8):1235-1245.
21. Brodaty H, Burns K. Noncognitive features of dementia. Nat Rev Neurol. 2012;8(6):307-316.
22. Padala PR, Burke WJ, Bhatia SC, Petty F. Selective serotonin reuptake inhibitor-induced apathy syndrome. Ann Pharmacother. 2012;46(11):152-156.
23. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3:CD003154.
24. Rosenberg PB, Lanctôt KL, Drye LT, Herrmann N, Scherer RW, Bachman D, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: The ADMET trial. J Clin Psychiatry. 2013;74(8):810-816.
25. Mintzer JE, Drye LT, Lanctôt KL, Rosenberg PB, Scherer RW, Herrmann N, et al. Effect of methylphenidate on apathy in Alzheimer's disease: The ADMET 2 randomised clinical trial. JAMA Neurol. 2021;78(11):1324-1332.
26. Padala PR, Burke WJ, Bhatia SC, Wengel SP. Treatment of apathy with bupropion and other dopaminergic agents. Clin Neuropharmacol. 2010;33(4):205-209.
27. Theleritis C, Politis A, Siarkos K, Lyketsos CG. Non-pharmacological interventions for apathy in dementia. Psychogeriatrics. 2018;18(4):265-275.
28. Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological interventions for agitation in dementia: Systematic review. Br J Psychiatry. 2014;205(6):436-442.
29. Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;(4): CD006489.
30. Ruthirakuhan M, Herrmann N, Abraham EH, Chan S, Lanctôt KL. Pharmacological and non-pharmacological interventions for apathy in Alzheimer's disease: A systematic review. Am J Geriatr Psychiatry. 2018;26(5):488-510.

About the Corresponding Author

Dr. Shahan Layek is an independent researcher based in West Bengal, India. His academic interests include research-oriented studies contributing to social sciences and humanities. He is engaged in scholarly work focusing on analytical and interdisciplinary perspectives, aiming to contribute to knowledge development through independent academic research and publications in his field.